Long-term use of low doses of aspirin daily reduces the incidence and mortality from colorectal cancer, a study reveals.
A meta-analysis of four randomised trials of aspirin compared with a control over 20 years found it reduced the long-term risk of colon cancer, but not rectal cancer.
The results, published in the Lancet, showed low doses of aspirin daily were as effective in reducing the incidence of colorectal cancer as higher doses.
Using data from a previous report the authors noted that the 20-year incidence of colorectal cancer was reduced by 30 per cent, when patients were treated with high daily doses (> 500mg) of aspirin for about five years.
“We have shown the same effect for 75 -300mg doses of aspirin, with 75mg...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.